Mounjaro®
Starting from £179.99/mo
Start journey Learn moreGallbladder pain is a recognised side effect of tirzepatide (Mounjaro) and a serious one at that. Weight loss itself — particularly rapid weight loss — increases the risk of gallstones forming, and Mounjaro's effect on gastric emptying can compound this. If you're experiencing upper-right abdominal pain, especially after eating, this page explains what may be happening, what the clinical evidence says, and when you need to stop reading and call for help. Mounjaro is a prescription-only medicine; every person starting or continuing treatment should have these risks discussed as part of their clinical assessment. Our clinical team covers gallbladder health as part of every prescribing conversation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It often starts like this: a dull ache after a meal, maybe some nausea you've been putting down to the usual early-dose adjustment. Gastrointestinal discomfort is common on tirzepatide, and most people assume any stomach-area pain is just that. Sometimes it is. But upper-right abdominal pain that comes on after eating (particularly after something fatty) has a different pattern to the typical nausea of a dose increase, and it's worth taking seriously.
The NHS medicines page for tirzepatide lists gallbladder problems, including gallstones (cholelithiasis) and inflammation of the gallbladder (cholecystitis), among the known side effects of Mounjaro. These aren't rare theoretical risks buried in a long list; they appeared in the SURMOUNT clinical programme and are flagged in the licensed product information. Our full overview of Mounjaro side effects covers the wider picture, but the gallbladder and its relationship with Mounjaro deserve their own careful attention.
The mechanism matters here. Mounjaro slows how quickly the stomach empties food into the small intestine. This is part of how it reduces appetite. But slower digestion also means bile (the digestive fluid stored in the gallbladder) sits for longer without being called into action. Bile that stagnates has a higher chance of forming crystals, then stones. Add to that the fact that losing weight quickly (which Mounjaro is very effective at doing) raises the cholesterol concentration in bile, and the conditions for stone formation become more favourable. Neither factor on its own is unique to Mounjaro, but they combine.
If you're feeling uncomfortable right now and wondering whether what you're experiencing could be gallbladder-related, that discomfort is understandable. Worth reading on.
The classic presentation of a gallbladder attack is a cramping, colicky pain in the upper-right quadrant of the abdomen, often starting 30 to 60 minutes after a meal and sometimes radiating up to the right shoulder or between the shoulder blades. It may be accompanied by nausea, vomiting, bloating, and (in more severe cases) fever or sweating. The pain often peaks and then eases over a few hours if the stone passes back out of the bile duct; if the gallbladder becomes infected or inflamed (cholecystitis), the pain tends to be more constant and may be accompanied by a fever.
This is different from the nausea and stomach upset that many people experience when first starting Mounjaro or after a dose increase. Those GI effects tend to be diffuse, come in waves, and settle within a few days to a fortnight as the body adjusts. Gallbladder pain tends to be more localised, more intense, and triggered by fatty food specifically. If you're unsure which you're dealing with, the safest approach is to speak to a clinician rather than wait it out.
For a more detailed look at how tirzepatide interacts with gallbladder function, the page on how Mounjaro affects the gallbladder covers the physiology further. If you've already had your gallbladder removed and are wondering whether Mounjaro is still suitable, the guide to Mounjaro without a gallbladder addresses that specifically.
Some symptoms need same-day or emergency assessment, not a wait-and-see approach. Contact your GP or call 111 promptly if you develop:
persistent or worsening pain in the upper-right abdomen, particularly if it lasts more than a few hours; pain that radiates to your right shoulder or back; fever alongside abdominal pain; yellowing of the skin or eyes (jaundice); dark urine or pale stools alongside any of the above.
Call 999 or go to A&E if the pain is sudden, severe, and spreading, particularly if it reaches your back along with vomiting. Severe, persistent upper-abdominal pain that radiates to the back can also be a sign of acute pancreatitis, which the MHRA flagged in a Drug Safety Update for GLP-1 medicines in January 2026 as an infrequent but serious side effect requiring urgent attention.
Do not reduce or stop your dose without telling whoever prescribed it. Stopping without clinical guidance can affect your treatment plan and (if you're on Mounjaro for type 2 diabetes as well as weight management) your blood sugar. If you've developed confirmed gallstones or had your gallbladder removed during treatment, our page on continuing Mounjaro after gallbladder removal covers what the evidence says about ongoing treatment.
Any suspected side effect from Mounjaro can be reported to the MHRA directly through the Yellow Card scheme. Reports from patients help build the post-market safety picture for relatively new medicines, and Mounjaro carries a Black Triangle (▼) designation precisely because active surveillance is ongoing.
Gallbladder risk doesn't make Mounjaro unsuitable for most people, and clinicians weigh it against the well-documented harms of untreated obesity, which include cardiovascular disease, type 2 diabetes, and joint disease. The key is having a proper clinical conversation about your individual risk before you start, and knowing what to watch for once you're on treatment.
At nume, a GPhC-registered Independent Prescriber reads every consultation personally, not software, not a template review. Side effects, including gallbladder risk, are part of that assessment. You can read more about our approach on the about us page, and our Mounjaro overview covers the full picture of how the medicine works and who it's licensed for.
If you're currently on treatment through another provider and have concerns, our prescribers can review your case as part of a transfer consultation, details are on the treatment page. And if you're weighing up the cost of private treatment alongside everything else, our weight loss treatment overview explains what's included in a transparent single price with no subscription attached.
Side effects that worry you deserve a clinical answer, not a forum thread. Start your free consultation and our prescribers will discuss suitability, your personal risk factors, and what to watch for once you begin.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.